Market

Eight years of data protection would remain, but baseline market protection would fall from two years to one under the EU’s near-final pharmaceutical overhaul. That change puts development economics alongside faster regulatory review as a board-level concern. Companies planning European programs

By the end of this decade, the medical imaging AI sector is expected to balloon to a valuation of $17.19 billion as digital diagnostics become a standard pillar of care. This monumental shift highlights how the medical field is rapidly outgrowing traditional manual interpretation, favoring instead

Institutional investors now manage portfolios by treating inadequate environmental, social, and governance strategies as material financial liabilities rather than mere corporate social responsibility gestures. This seismic shift marks the end of an era where pharmaceutical companies could rely on

Rising operational costs and increased patient acquisition expenses are forcing behavioral health providers to prioritize sustainable efficiency over broad geographic reach. The era of the rapid "land grab" that dominated the early 2020s has given way to a more disciplined approach where investors

With more than 80 percent of trial participants achieving clear or almost clear skin, nomelcitinib is positioning itself as a robust competitor in the psoriasis treatment landscape. The quest for a highly effective, oral, and safe treatment for autoimmune skin conditions has long been the primary

Ethiopia's strategy reflects a broader continental trend toward health security, where local production is viewed as the only viable path to effective public health response. By 2030, the nation intends to transition from a major importer of medical goods to a self-reliant manufacturing powerhouse,